Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemohyperthermia With Mitomycin-C Before TURBT vs Postoperative Mitomycin-C in NMIBC
2024-519890-21-00Phase 4Authorised
- Sponsor
- Hospital Universitario de Canarias
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mitomycin c in bladder cancer (2 arms), sponsored by Hospital Universitario de Canarias. Primary endpoint: Early recurrence rate of non-muscle invasive bladder cancer. Planned start Nov 2024; status: authorised.
02
Drugs
mitomycin c
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2024-519890-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519890-21-00.